You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Illumina had argued that Complete Genomics' patent covering two-color sequencing-by-synthesis chemistry was obvious, but the US PTAB disagreed.
The Broad Institute called UC's new legal strategy "deeply unfortunate" and called on the university to "move beyond litigation."
As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.
The process challenges claims made in certain UC Berkeley patents on the use of CRISPR-Cas9 to edit eukaryotic genomes.
The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.
The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.
Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.
The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.
Michelle Lee, the director of the United States Patent and Trademark Office, has resigned, IP Watchdog reports.
The University of California is appealing the recent CRISPR/Cas9 patent decision.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.